Cytoreductive Nephrectomy May Still Remain Standard For Some With Metastatic Renal Cell Carcinoma

The addition of cytoreductive nephrectomy to treatment with sunitinib malate did not provide a survival benefit for intermediate and poor-risk patients with metastatic renal cell carcinoma, according to results of the phase 3 CARMENA clinical trial presented at ASCO Annual Meeting.08/06/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news